Apolipoprotein E genetic variation and statin therapy appointment
Loading...
Date
2016-05
Authors
Kassenova, A.
Kossumov, A.
Nurgozhin, T.
Supiyev, A.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Dyslipidemia is an important risk factor for cardiovascular disease due to the
significant influence of cholesterol on atherosclerosis. Several genetic variants in genes related
with triglyceride (TG) metabolism has been described, including LPL, apolipoprotein A5 and
apolipoprotein E (Apo E) are associated with dyslipidemia by involvement to lipid metabolism. The
combined analysis of these polymorphisms could produce clinically meaningful complementary
information. Changes in TG levels are now considered an independent cardiovascular risk
factor; hence, the study of combined variants in genes involved in TG metabolism may help
explain part of the risk for CVD. The most informative polymorphisms within the Apo E gene are
the Arg158Cys (rs7412) and Cys112Arg (rs429358) which define Apo E gene alleles, epsilon2,
3 and 4 (£2, £3 and £4).
Description
Keywords
Dyslipidemia, apolipoprotein, genotype, statin therapy
Citation
A. Kassenova, A. Kossumov, T. Nurgozhin, and A. Supiyev. 2016. Apolipoprotein E genetic variation and statin therapy appointment. Abstract book. 4 th International Scientific Conference “Regenerative medicine & healthy aging”. National Laboratory Astana, Nazarbayev University. http://nur.nu.edu.kz/handle/123456789/1503